The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice (Q38363214)

2 September 2017

title

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice (English)

1 reference

2 September 2017

0 references

Lotte Bjerre Knudsen

7

0 references

Carolyn F. Deacon

object named as

Carolyn F Deacon

4

0 references

author name string

Bidda Rolin

1

1 reference

2 September 2017

Marianne O Larsen

2

1 reference

2 September 2017

Carsten F Gotfredsen

3

1 reference

2 September 2017

Richard D Carr

5

1 reference

2 September 2017

Michael Wilken

6

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

American Journal of Physiology - Endocrinology and Metabolism

2 September 2017

published in

1 reference

2 September 2017

volume

283

1 reference

2 September 2017

issue

4

1 reference

2 September 2017

page(s)

E745-52

1 reference

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

beta-cell glucotoxicity in the Psammomys obesus model of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

Secretion of the Incretin Hormones Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide Correlates with Insulin Secretion in Normal Man Throughout the Day

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00030.2002

10.1152/AJPENDO.00030.2002

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference